Lilly's growth outlook is improving through cutting costs and launching several drugs.
Eli Lilly’s fourth-quarter outperformance versus both our and consensus expectations combined with tax-rate guidance 250 basis points below our expectations will likely lead to a minor fair value estimate increase, and we view the stock as slightly undervalued. Lilly’s strong new drug growth reinforces our conviction in the firm’s wide moat rating as innovation is offsetting the generic competition on older drugs.In the quarter, new drugs added over $700 million in incremental sales to Lilly’s ...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.